JNJ•benzinga•
Johnson & Johnson Highlights Multiple Blood Cancer Trial Data At ASCO Presentation
Summary
Johnson & Johnson shared positive ASCO 2025 results, including improved survival and remission in prostate and multiple myeloma patients.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 3, 2025 by benzinga